Moving
KalshiCloses January 1, 2027

When will the FDA approve Compass Pathways' COMP360 Psilocybin?

Before 2028 leads at 92% (about 9 in ten) on Kalshi, as of Nov 3, 04:19 UTC. It's up 1.5 points in the last 24 hours.

Before 2028 92% ▲ 1.5 pts · 24h

The odds

as of Nov 3, 04:19 UTC
  • Before 2028 92% +1.5
  • Before July 2027 87% —
  • Before October 2027 83% —
  • Before Mar 1, 2027 67% —
  • Before Jan 1, 2027 18% +45

Each outcome here is its own yes/no question, so the chances don't add up to 100%.

Traded today$1K
Traded in all$26K
Favourite, 7 days+1.5 pts

Before 2028, the last 7 days

Kalshi price
25%50%75%Oct 26Nov 291%

Oct 26: 90% · Oct 27: 90% · Oct 28: 91% · Oct 29: 90% · Oct 30: 90% · Oct 31: 90% · Nov 1: 90% · Nov 2: 91%

How it resolves

Kalshi's rule, word for word
(Each outcome is its own contract. This is the rule for the favourite, Before 2028; the others read the same way with their own outcome.) If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.

Settlement sources: U.S. Food and Drug Administration.; FDA; Compass Pathways

See it on Kalshi ↗

Tech & science

More markets like this

All →